Enliven Therapeutics (NASDAQ:ELVN) Insider Sells $81,000.00 in Stock

Key Points

• Insider Joseph Lyssikatos sold 4,000 shares of Enliven Therapeutics (NASDAQ:ELVN) for a total of $81,000, decreasing his ownership by 0.43% to approximately 927,688 shares.
• Enliven Therapeutics has a market cap of $1.21 billion and reported a quarterly EPS of ($0.49), exceeding analyst expectations.
• Analysts have upgraded Enliven Therapeutics with multiple "buy" ratings and raised price targets, with the average target now at $41.20.

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) insider Joseph Lyssikatos sold 4,000 shares of the stock in a transaction on Friday, September 26th. The shares were sold at an average price of $20.25, for a total value of $81,000.00. Following the transaction, the insider directly owned 927,688 shares of the company's stock, valued at approximately $18,785,682. This trade represents a 0.43% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Enliven Therapeutics Price Performance

Shares of Enliven Therapeutics stock traded up $0.17 during trading hours on Tuesday, reaching $20.47. The company had a trading volume of 402,428 shares, compared to its average volume of 400,067. Enliven Therapeutics, Inc. has a one year low of $13.30 and a one year high of $30.03. The business has a fifty day simple moving average of $19.77 and a 200 day simple moving average of $19.60. The firm has a market cap of $1.21 billion, a PE ratio of -10.24 and a beta of 0.88.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last posted its quarterly earnings results on Wednesday, August 13th. The company reported ($0.49) EPS for the quarter, topping analysts' consensus estimates of ($0.53) by $0.04. On average, research analysts forecast that Enliven Therapeutics, Inc. will post -1.95 EPS for the current year.

Institutional Investors Weigh In On Enliven Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in ELVN. TCG Crossover Management LLC purchased a new stake in shares of Enliven Therapeutics in the second quarter worth $9,990,000. Duquesne Family Office LLC purchased a new stake in shares of Enliven Therapeutics in the second quarter worth $9,288,000. Candriam S.C.A. purchased a new stake in shares of Enliven Therapeutics in the second quarter worth $8,358,000. Franklin Resources Inc. raised its position in Enliven Therapeutics by 2,029.3% during the second quarter. Franklin Resources Inc. now owns 430,240 shares of the company's stock valued at $8,631,000 after purchasing an additional 410,034 shares in the last quarter. Finally, Affinity Asset Advisors LLC purchased a new stake in Enliven Therapeutics during the second quarter valued at about $8,024,000. Hedge funds and other institutional investors own 95.08% of the company's stock.

Wall Street Analysts Forecast Growth

ELVN has been the subject of a number of analyst reports. Robert W. Baird raised their price target on Enliven Therapeutics from $40.00 to $52.00 and gave the stock an "outperform" rating in a report on Monday, June 16th. HC Wainwright raised their price target on Enliven Therapeutics from $40.00 to $48.00 and gave the stock a "buy" rating in a report on Wednesday, July 2nd. Finally, The Goldman Sachs Group initiated coverage on Enliven Therapeutics in a report on Monday, June 16th. They issued a "buy" rating and a $37.00 price target for the company. Five research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company presently has an average rating of "Buy" and an average price target of $41.20.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.